Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351

Journal of Steroid Biochemistry and Molecular Biology

Volumn 76, Issue 1-5, 2001, Pages 61-70

  Levenson, Anait S ^a   Macgregor Schafer, Jennifer I ^a   Bentrem, David J ^a   Pease, Katherine M ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; Surface amino acid; Tamoxifen estrogen receptor complex

Indexed keywords

4 HYDROXYTAMOXIFEN; ACOLBIFENE; AMINO ACID; ANTIESTROGEN; ASPARTIC ACID; COMPLEMENTARY DNA; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GLYCINE; GW 7604; RALOXIFENE; RECEPTOR SUBTYPE; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; BREAST CARCINOMA; CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; DNA TRANSFECTION; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENDOMETRIUM CARCINOMA; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

AMINO ACIDS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, NORTHERN; BREAST NEOPLASMS; ESTROGENS; HUMANS; RECEPTORS, ESTROGEN; RNA, MESSENGER; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 0034989904     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(00)00143-6     Document Type: Article

References (45)

1. Basic guides to the mechanism of estrogen action
2. The clinical potential of new antiestrogens
3. Tamoxifen for early breast cancer: An overview of the randomized trials
4. Tamoxifen and contralateral breast cancer
5. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
6. Risk of endometrial cancer after tamoxifen treatment of breast cancer
7. Molecular mechanism of resistance to tamoxifen therapy in breast cancer
8. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium
9. Drug resistance to tamoxifen during breast cancer therapy
10. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer
11. Tamoxifen-induced tumor stimulation and withdrawal response
12. Clinical significance of tamoxifen withdrawal response
13. Response after withdrawal of tamoxifen and progestogen in advanced breast cancer
14. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
15. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
16. Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy
17. MCF-7: The first hormone-responsive breast cancer cell line
18. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens
19. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro
20. Acquired tamoxifen resistance: Correlatrion with reduced breast tumor levels of tamoxifen and izomerization of trans-4-hydroxytamoxifen
21. Investigation on the mechanism of tamoxifen-stimulated breast tumor growth using nonisomerizable analogs of tamoxifen and metabolites
22. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
23. Characterization of tamoxifen-stimulated MCF-7 tumor variants grown in athymic mice
24. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain
25. Peptide antagonists of the human estrogen receptor
26. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor
27. Estrogenic activity is increased for an antiestrogen by natural mutation of the estrogen receptor
28. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (Aspartate) in the estrogen receptor
29. Estradiol regulation of components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the estrogen receptor
30. Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) endogenous gene expression in breast cancer cells
31. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor
32. Molecular basis of agonism and antagonism in the oestrogen receptor
33. The structural basis of estrogen receptor/co-activator recognition and the antagonism of this interaction by tamoxifen
34. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor
35. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog
36. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
37. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro
38. Ligand interaction at the estrogen receptor to program antiestrogen action: A study with non-steroidal compounds in vitro
39. Molecular mechanism of action of a new clinically relevant antiestrogen (GW 7604) related to tamoxifen
40. (S)-(+)-[4-[7-2, 2-Dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy] phenyl]-2H-1-benzopyran-3-yl]phenyl]-2, 2-dimethylpropanoate (EM-800): A highly potent, specific and orally active nonsteroidal antiestrogen
41. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors
42. Estrogen receptor mutations in tamoxifen-resistant breast cancer
43. Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens
44. Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens
45. Identification of a third autonomous activation domain within the human estrogen receptor